FIVE PRIME THERAPEUTICS, INC. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016
Collaboration and license revenue
Revenue
Collaboration revenue
License revenue
Total revenue
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Interest income
Other expense, net
Other loss, net
Other income, net
Loss before income tax
Income tax benefit
Net loss
Basic
Diluted
Other comprehensive (loss) gain:
Unrealized (loss) gain on marketable securities, net of tax
Comprehensive loss
Basic and diluted net loss per share
Weighted-average shares used to compute basic and diluted net loss per common share

Comments